BPC-157 and TB-500 are entering formal trials — here is the 2026 data.

Why two trials is a bigger deal than it looks

BPC-157 (body protection compound, a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice) and TB-500 (a synthetic fragment, residues 17–23, of the larger 43-amino-acid protein thymosin beta-4) have spent the better part of fifteen years as the most-discussed peptides in injury recovery and the least-studied in formal human trials. As of 2025, peer-reviewed reviews still described the BPC-157 evidence base as preclinical with only minor Phase 1 and small inflammatory-bowel-disease work to point to in humans ³.

That changed in early 2026. Hudson Biotech registered two trials within days of each other. NCT07437547 is a 120-patient Phase 2, double-blind, placebo-controlled trial of injectable BPC-157 for acute grade II hamstring muscle strain, with magnetic resonance imaging (MRI) confirmation of injury at entry and a co-primary endpoint of time to return to unrestricted sport plus change in MRI injury volume at day 14 ¹. NCT07487363 is an 80-patient Phase 1/2, double-blind, placebo-controlled, sequential dose-escalation study of TB-500 (the thymosin beta-4 17–23 fragment) in adults with stable atherosclerotic cardiovascular disease, with safety endpoints and exploratory biomarkers of vascular function and inflammation ².

Neither trial is a Phase 3 confirmatory study, and neither is a U.S. FDA approval pathway. But both are properly registered, double-blind, placebo-controlled, with independent safety monitoring committees, and pre-specified endpoints. That is a different category of evidence than the case series and animal work that have carried these compounds in the conversation up to now. It is also the first time the recovery-peptide pair has shown up together in a formal trial registry within the same calendar quarter.

Mechanism: the signal both peptides pull

BPC-157 and TB-500 are often grouped because both have been credited with accelerating soft-tissue repair, but the signal each one pulls is different.

BPC-157 is a pentadecapeptide (sequence GEPPPGKPADDAGLV) originally isolated from human gastric juice and characterised by Predrag Sikiric and the Zagreb pharmacology group. The peptide is unusual in being stable in human gastric juice for more than 24 hours and showing no LD1 (lowest lethal dose) in animal toxicity testing ⁴. The signal it pulls is best described as a vascular and cytoprotective one: increased expression of vascular endothelial growth factor receptor 2 (VEGFR2), nitric oxide synthase (NOS) activity, and a fibroblast and endothelial cell migration response that drives angiogenesis — the formation of new blood vessels in injured tissue. The 2020 Drug Design Development and Therapy paper on clopidogrel-induced gastric injury in rats is a clean illustration: BPC-157 reversed clopidogrel-induced suppression of VEGFR2 and endothelial NOS, restored mucosal angiogenesis, and reduced inflammation and apoptosis — the same triad shows up across BPC-157 wound-healing models in skin, gut, muscle, tendon, ligament, bone, and cornea ⁵.

TB-500 is a synthetic 17–23 fragment of thymosin beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein that the body produces naturally. Native thymosin beta-4 is one of the most abundant intracellular proteins, with documented roles in actin cytoskeleton remodeling, cell migration, and tissue repair after injury. The signal it pulls is closer to a regenerative one: it activates resident epicardial progenitor cells, stimulates cardiomyocyte and endothelial cell proliferation, modulates inflammation, and promotes angiogenesis in injured cardiac and skeletal muscle ⁶. In a 2021 porcine model of acute myocardial infarction, thymosin beta-4 delivered from gelatin microspheres co-administered with human-induced pluripotent stem-cell-derived cardiomyocytes significantly enhanced engraftment, improved left ventricular systolic function, and reduced infarct size compared to either treatment alone ⁷. In rodent post-MI work, monocyte-membrane-modified extracellular vesicles loaded with thymosin beta-4 reduced myocardial fibrosis and increased vascular density relative to controls ⁸.

Two peptides, two different signals. BPC-157 looks more like a general cytoprotectant that pulls a vascular-protection and repair signal across most tissue types. TB-500 looks more like a targeted regenerative signal in muscle — especially cardiac muscle — with a documented progenitor-cell activation component the BPC-157 literature does not claim.

The shared piece: angiogenesis

What the two compounds genuinely share is the angiogenic step. Both have been shown to drive new blood-vessel formation in injured tissue, which is the rate-limiting step in many recovery contexts — tendon, ligament, post-MI cardiac muscle, and chronic wounds ^{4 6}. That overlap is part of why the two peptides get stacked in community-use protocols even though their underlying signals are not the same. In tissue that is poorly vascularised at baseline — which is most tendon and most chronic injury — restoring blood supply is what actually rate-limits everything else.

BPC-157 in trial: BPC-HAMSTR and what came before

BPC-HAMSTR (NCT07437547) is the highest-quality human BPC-157 protocol on the registry as of May 2026. The headline elements:

• Design. Randomized, double-blind, placebo-controlled. 1:1 allocation to subcutaneous BPC-157 or matching placebo, daily for 14 days.
• Population. 120 adults aged 18–45 with an acute (within 72 hours) MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus. Recreational athletes or better at baseline.
• Co-primary endpoints. Time to return to unrestricted sport (cleared by a blinded sports-medicine clinician plus a standardized functional-performance battery), and change in MRI-assessed injury volume at day 14 measured by blinded central radiology review.
• Secondary endpoints. Pain on a 0–10 numeric rating scale during activity, isokinetic hamstring strength limb-symmetry index, Lower Extremity Functional Scale (LEFS, 0–80) at 56 days.
• Status. Recruiting. Estimated primary completion 14 February 2027 ¹.

Before BPC-HAMSTR, the human BPC-157 registry was thin. NCT02637284 was a 42-volunteer Phase 1 pharmacokinetics and safety study of oral BPC-157 (PCO-02, 1 mg per tablet) in healthy adults at Hospital Angeles Tijuana, Mexico, completed in 2016 ¹¹. That study reported no serious adverse events related to study medication but never produced a published efficacy readout in a major journal. The 2025 Pharmaceuticals literature and patent review described BPC-157 as having a "desirable safety profile" in available data and noted that the World Anti-Doping Agency (WADA) temporarily banned the compound in 2022 but did not retain the ban on its current prohibited list ³.

The animal literature behind BPC-HAMSTR is, by the standards of unapproved peptides, unusually deep. The Zagreb group has published dozens of rat and mouse models across tendon, ligament, bone, skin, cornea, gastrointestinal tract, and spinal cord injury, with consistent angiogenic and repair signals ⁴. That preclinical depth is part of why a properly designed Phase 2 was eventually worth running. It is also why BPC-HAMSTR matters: of the peptides routinely sold and self-administered in the recovery space, BPC-157 has the clearest preclinical case to make a return-to-sport claim — and now there is a registered trial that will either support or refute that case in a blinded, MRI-confirmed population.

TB-500 in trial: TBRIDGE-CV and the cardiac story

The TB-500 trial (TBRIDGE-CV, NCT07487363) is a different shape. It is a Phase 1/2 sequential dose-escalation study in 80 adults aged 40–75 with stable atherosclerotic cardiovascular disease (ASCVD) on guideline-directed therapy. Participants are randomized 3:1 to TB-500 or placebo within three sequential dose cohorts. The primary endpoints are safety: incidence of treatment-emergent adverse events and serious adverse events. Secondary endpoints are mechanistic: change in brachial artery flow-mediated dilation (a measure of endothelial function), high-sensitivity C-reactive protein (a marker of vascular inflammation), and NT-proBNP (a marker of cardiac stress). An independent safety review committee gates each dose escalation ².

TBRIDGE-CV is not the first thymosin beta-4 cardiac trial. The full-length recombinant human thymosin beta-4 protein has been through Phase 1, 2a, and now a Phase 2b in acute myocardial infarction by Beijing Northland Biotech, with a Phase IIc study registered as not-yet-recruiting in May 2026. The completed Phase 2a study (NCT05485818) randomized 62 adults with acute myocardial infarction across low, middle, and high dose arms plus placebo ¹². The larger full-length thymosin beta-4 development program is a different molecule from TB-500 — TB-500 is the seven-amino-acid active fragment, not the parent protein — but the parent program provides the regulatory and mechanistic backdrop for why a TB-500 trial in vascular biology is a credible next step.

Outside cardiology, the larger Tβ4 program has produced a completed Phase 3 in dry eye (the RGN-259 ARISE-3 trial, 700 patients, primary completion 2020) and an ongoing Phase 3 in neurotrophic keratopathy (SEER-2, recruiting, primary completion April 2026). Those are topical formulations of full-length thymosin beta-4 for ophthalmic indications, not TB-500 in muscle or vascular tissue, but they establish that a thymosin beta-4 molecule has cleared a Phase 3 endpoint and survived regulatory review — which is more than can currently be said for any BPC-157 indication. The 2020 Current Medicinal Chemistry review on thymosin beta-4 in heart injury catalogues the mechanism case across cardiac, neural, and skeletal muscle repair ⁶.

Delivery: subcutaneous is a feature, not a limitation

Both BPC-157 and TB-500 are peptides. Peptides get degraded by the gut's proteolytic environment, which is why the trial protocols use subcutaneous injection — the same route that carries semaglutide, tirzepatide, the entire growth-hormone- releasing peptide class, and most peptide therapeutics that actually work in humans.

Subcutaneous delivery is the feature that makes the signal possible, not a limitation that needs an oral workaround. The oral PCO-02 BPC-157 program produced pharmacokinetic data in 42 healthy volunteers a decade ago and has not, in the time since, delivered a published Phase 2 efficacy readout the way a successful oral formulation would have. The 2025 BPC-157 literature review explicitly notes that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans" — and the human studies that have been done are predominantly the oral and IBD work that did not produce a clear efficacy signal ³. BPC-HAMSTR is subcutaneous. That is the choice the trial sponsors made for a reason.

In community use, people self-administering BPC-157 and TB-500 for injury recovery are almost universally using subcutaneous or intramuscular injection rather than oral formulations. The rationale — bypass first-pass hepatic metabolism, deliver intact peptide to systemic circulation, allow precise dosing — is the same rationale the trial sponsors used. Framing "no needles" oral versions as upgrades misses the trade. They sacrifice the very delivery advantage that makes the peptide class work.

A tiered framework for thinking about it

With two Phase 2 trials underway but no approved indication anywhere in the world, the honest answer for most readers is to wait for the readouts. The following framework is for thinking about how to position the peptide pair in a recovery context, not a protocol to start tomorrow.

Foundational tier — what works regardless. Sleep, protein intake at 1.6–2.2 g/kg of reference body weight, progressive loading of the injured tissue once acute inflammation resolves, and zone-2 cardiovascular work to support peripheral angiogenesis. None of that requires an injection. All of it has Phase 3-level evidence behind it for soft-tissue recovery. The recovery and pain hub walks through the broader foundational work the peptide conversation tends to skip.

Research-curious tier — the trial population. Adults with an acute grade II hamstring strain meeting BPC-HAMSTR inclusion criteria could, in principle, contact the recruiting site listed on the trial record. That is the only regulator-sanctioned route to clinical-grade BPC-157 in 2026. For TB-500, the equivalent population is adults aged 40–75 with stable ASCVD considering TBRIDGE-CV enrollment. Both trials run through Peking University Shenzhen Hospital as the single registered site, which constrains geographic availability sharply ^{1 2}.

Experimental tier — off-label community use. This is the tier where most current BPC-157 and TB-500 use actually lives. It is also where the evidence is weakest, the vendor quality most variable, and the safety monitoring non-existent. We name the tier honestly because pretending it does not exist would be dishonest; we do not endorse it because the safety, identity, and purity questions below are unresolved.

Grey areas: vendor quality, WADA, and FDA status

Three issues sit between the trial protocols and the way these peptides are actually used outside trials.

Vendor quality. The peptides sold online as "research chemicals" or "for laboratory use only" are not manufactured under good manufacturing practice (GMP), are not independently identity-tested in most cases, and are not pharmacy-dispensed. The 2025 BPC-157 review specifically flagged that the compound is offered for sale on many websites without regulatory approval — which is a description of the market, not a verdict on any individual vendor ³. There is no public, independent reference dataset that lets a consumer verify whether a given vial contains what its label says it contains. Mass-market peptide product is not equivalent to clinical-grade trial material. Anyone framing it as such is overstating the evidence.

WADA status. The World Anti-Doping Agency temporarily added BPC-157 to its prohibited list in 2022 under the S0 category for non-approved substances. As of the 2025 Pharmaceuticals review, BPC-157 was not listed on the current WADA prohibited list — but BPC-HAMSTR explicitly excludes participants "currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict" unless explicitly approved by the relevant authority ^{1 3}. Tested athletes should treat the situation as ambiguous and verify their sport's specific policy before any use.

FDA status. Neither BPC-157 nor TB-500 is FDA- approved. Neither has a route to the U.S. compounding pharmacy system in 2026 — the FDA has historically excluded BPC-157 from the bulk-drug substance lists that authorize 503A compounding. That is not changing on the timeline of the current Phase 2 trials. Whether positive readouts from BPC-HAMSTR or TBRIDGE-CV move the regulatory needle is a question for 2028 at the earliest, given the typical Phase 2 to Phase 3 development gap.

What we still do not know

The 2026 trial registrations are progress. They are not evidence of efficacy. Five questions remain genuinely open.

Whether BPC-HAMSTR hits its primary endpoint. Phase 2 trials in musculoskeletal injury frequently fail to separate from placebo on return-to-sport endpoints because the rehabilitation arm itself is so effective. A null result would be informative; a positive one would shift the conversation substantially.

Whether TBRIDGE-CV produces a clean safety profile across the dose-escalation cohorts. The TB-500 fragment has substantially less human exposure data than full-length thymosin beta-4. A safety signal in the higher-dose cohorts would constrain the broader Tβ4 development program.

Whether the tendon and ligament repair signals from the animal literature translate to humans. BPC-HAMSTR is a muscle-strain trial. The most-cited preclinical claims for BPC-157 are tendon and ligament. Those indications are not yet in registered human trials at Phase 2 quality.

Whether the long-term safety profile holds up at clinically meaningful exposures. The available human safety data covers short courses (weeks, not months). Chronic or repeated-cycle use, which is how the peptides are used in community settings, has no human safety dataset behind it.

Whether clinical-grade material becomes available if the Phase 2 readouts are positive. Even successful Phase 2 data does not guarantee a Phase 3 sponsor or a regulatory path. The history of small peptide development is full of compounds that got to Phase 2 and never got a development partner to take them through to approval. The 2026 Frontiers in Aging review of therapeutic peptides for healthy aging flagged BPC-157 and TB-500 specifically as having "promising preclinical and limited clinical evidence" that "lack long-term safety data and systematic validation" ⁹.

The honest read on May 2026: the recovery-peptide duo has its first properly designed human evidence in motion. The trials will either substantiate or fail to substantiate the claims that have surrounded these compounds for a decade. Until they report — 2027 at the earliest — the gap between what is known and what is claimed is still wider than most of the marketing copy on the internet suggests.